Vivo Returns to Cell Therapy Play
19 Nov 2026
US$ 20.00
Vivo Capital has made a follow-on investment in the near Rmb100 m (US$15 m) series B funding round of Wuxi Genyrel ......
Related Publications
HongShan Capital Group was party to the series A funding round of Genesis AI, a general-purpose robot developer ......
Shunwei Capital has led the near Rmb100 m (US$15 m) pre-series A+ funding round of NovaSilicon, an AI-native chip ......
Connect With Us
We love to share Asia PE insights and news from time to time. Drop us your email address if you like to hear from us.
Rest assured that your email address will not be shared, as we hate spams as much as you do.

